Alliance Global Partners lowered the firm’s price target on Barinthus Biotherapeutics to $9.50 from $11 and keeps a Buy rating on the shares post the Q2 report. The company emphasied the ongoing development of its lead VTP-300 product candidate, a T-cell stimulating immunotherapeutic, in chronic hepatitis B virus, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BRNS: